We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Vital Biosciences Unveils Revolutionary POC Lab Testing Platform

By LabMedica International staff writers
Posted on 26 Jul 2023

Vital Biosciences (Toronto, ON, Canada) is making waves at AACC 2023 with the introduction of its game-changing product, the VitalOne. More...

This groundbreaking innovation with the potential to completely redefine diagnostics was unveiled to thousands of laboratory experts at the AACC annual gathering. Furthermore, VitalOne was recognized as the Audience Choice winner at this year's AACC Disruptive Technology Award.

For years, routine lab testing has been a cornerstone of clinical guidelines. Currently, medical decisions rely on laboratory test results 70% of the time. However, it's concerning that nearly 30% of electronic lab orders remain unfulfilled. For instance, about 20% of American adults with diabetes remain undiagnosed, and a staggering 80% of prediabetic individuals are oblivious to their condition. Preventing chronic diseases such as hyperlipidemia, type 2 diabetes, or congestive heart failure is best achieved through early detection and intervention. Unfortunately, the existing testing, diagnosis, and treatment process is not universally accessible.

The VitalOne aims to democratize blood diagnostics by making over 50 lab-grade tests — covering 95% of routine lab orders — available at primary care locations, all packaged within a device no bigger than a desktop computer. With VitalOne, physicians can conduct tests, diagnose, and treat patients all in one appointment, with results obtained in 20 minutes. The underlying technology has been rigorously tested and validated against thousands of samples in comparison to gold-standard instruments, through collaborations with Vital's lab partners.

Vital is redefining point-of-care testing with the development of the VitalOne, envisaging a future where patients do not need to sacrifice work hours, commute between their primary care doctor and a lab, or endure days of waiting to discuss their results. Bridging this gap will make diagnostics more accessible and speed up clinical interventions, helping prevent adverse outcomes and disease progression. VitalOne is currently in its late-stage product development and is yet to be made commercially available. Additional clinical studies are scheduled for later this year. Moreover, Vital is keen on forming partnerships with industry, academia, and the laboratory medicine community for further performance evaluations and feedback.

“We started Vital to make high-quality care more accessible to millions of people and realized how limited we were by our current diagnostic infrastructure,” said Vasu Nadella, CEO and Co-Founder of Vital Biosciences. “We seek to disrupt the USD 85 billion diagnostics industry by bringing lab-grade diagnostics everywhere and eliminating the impediments to proactive and accessible care.”

“We live in a world where you can order a pizza and have it delivered in 20 minutes but your lab results take days. That’s not okay,” added Mounir Koussa, Co-Founder and VP of Research and Development at Vital. “We want to ensure that diagnostics are available wherever and whenever they are needed, and that testing never becomes an impediment to treatment and care.”

Related Links:
Vital Biosciences


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
New
Mini Vortex Mixer
Vornado
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The proprietary multiomic platform unlocks disease-associated biomarkers from a range of biological sources (Photo courtesy of Tagomics)

Highly Sensitive and Specific Test to Enable Early Detection of Colorectal Cancer

A highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer could enable treatment at the earliest possible stages of disease development. Tagomics Ltd.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The LIAISON PLEX® Gram-Positive Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.